NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/11/2025
Voltar para busca
Dado oficial do USPTO
CANIFERON
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
23/11/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
16/09/2021
Data de registro
31/01/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/01/2023
Última transação
23/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
BODRI,KRISTIN MARIE
Localização atual
Historical data usage
Titulares e representantes
Titulares
ILC Therapeutics Limited
Representantes
Brian M. Davis VLP Law Group LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
[ Pharmaceuticals, medical and veterinary preparations for use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; pharmaceutical, medical and veterinary preparations for prevention, diagnosis and treatment of skin diseases; pharmaceutical, medical and veterinary preparations for dermatitis; pharmaceutical, medical and veterinary preparations for inflammatory diseases; medicines for veterinary purposes for use in the treatment of cancer, skin disorders and inflammatory diseases; pharmaceutical, medical and ] veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, dermatitis, skin diseases, * pruritic conditions, coronavirus and allergies * [ and inflammatory diseases; pharmaceutical, medical and veterinary preparations containing alpha interferon for the prevention, diagnosis and treatment of diseases and disorders, namely, cancer, dermatitis, skin diseases and inflammatory diseases, for animals; pharmaceutical, medical and veterinary drugs for use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biological preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; biological reagents being pharmaceutical preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; biological tissue cultures for medical use; biochemical preparations for medical use in the treatment of skin diseases, cancer, pruritic disorders and inflammatory diseases; anti-viral agents; diagnostic preparations for medical and veterinary purposes; clinical diagnostic reagents for medical and veterinary purposes; immunoassay reagents for medical use ]
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
13/05/2025
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
01/05/2025
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
24/04/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/04/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
11/10/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/05/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/05/2023
FIMP
FINAL DISPOSITION PROCESSED
05/05/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
31/01/2023
DOCK
ASSIGNED TO EXAMINER
13/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/11/2022
PUBO
PUBLISHED FOR OPPOSITION
15/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/10/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/10/2022
RFNT
REFUSAL PROCESSED BY IB
19/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
24/06/2022
RFRR
REFUSAL PROCESSED BY MPU
24/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/06/2022
CNRT
NON-FINAL ACTION WRITTEN
21/06/2022
DOCK
ASSIGNED TO EXAMINER
21/06/2022
MAFR
APPLICATION FILING RECEIPT MAILED
14/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/12/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CANIFERON ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.